Alabama House Bill HB118

Alabama 2026 Regular Session

• Introduced: 1/13/26
• Refer: 1/13/26

Caption

Abortion-inducing drugs; manufacture, distribution, and transport prohibited, exceptions provided, qui tam suit against certain persons who violate prohibition authorized and provided for, remedies provided

Impact

The implementation of HB 118 could significantly affect state laws governing healthcare, particularly concerning reproductive health. By banning the manufacture and distribution of abortion-inducing drugs, the bill aims to restrict access to medication-assisted abortion services. Proponents argue that this aligns with protecting fetal life and public health, while opponents claim it undermines women's rights and access to necessary medical care. The bill's provisions for legal action against violators introduce a new dimension of enforcement that could lead to increased litigation related to reproductive healthcare.

Summary

House Bill 118 prohibits the manufacture, distribution, and transport of abortion-inducing drugs except under specific exceptions. The bill outlines the legal framework for enforcing this prohibition, including the possibility of qui tam suits, which allows individuals to sue on behalf of the state for violations. This legislation reflects ongoing debates around reproductive rights and healthcare access, particularly regarding the regulation of pharmaceuticals associated with abortion procedures.

Contention

The contentious nature of HB 118 arises from its implications for reproductive rights in the state. Advocates for the bill view it as a critical measure for protecting unborn children, emphasizing the potential dangers associated with unregulated abortion-inducing drugs. Conversely, critics, including women's health advocates and certain legal experts, argue that the bill represents a regression in women's rights, limiting their autonomy over healthcare decisions. The potential for qui tam lawsuits might also lead to abuses where individuals target healthcare providers, raising ethical concerns about the impact on patients and doctors alike.